secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015702
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical Q3 2024 revenue $185K (+351% YoY); net loss $4.6M; CMS coverage secured
--------------------------------------------------------------------------------

- Revenue of $185K in Q3 2024, up 351% from $41K in Q3 2023.
- Net loss of $4.6M improved from $10.8M in Q3 2023; driven by fair value changes on convertible notes.
- Cash and short-term investments of $28.3M as of September 30, 2024.
- CMS Category B coverage secured for vCLAS catheter in FULCRUM-VT IDE study for drug-resistant VT.
- First procedures performed in FULCRUM-VT pivotal study; 206 patients at 20 US/Canadian centers to support FDA PMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000155837024015702/0001558370-24-015702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000155837024015702/adgm-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer